WuXi bulks up on biologics, cell therapies

The acquisition of genomic analysis and bioinformatics company NextCODE Health may give Chinese bellwether CRO WuXi PharmaTech Inc. (NYSE:WX) what it needs to climb the next evolutionary rung in genomics.

The $65 million cash deal for the company that was spun out of deCODE genetics Inc. allows WuXi to create genomic and bioinformatic products for personalized medicine, WuXi CFO and Venture Fund Chief Investment Officer Edward Hu told BioCentury...